Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study

C. F. De Oliveira, A. J. Lacave, C. Villani, J. P. Wolff, F. Di Re, M. Namer, A. Maskens, M. George, O. Dalesio, N. Rotmensz, J. B. Vermorken

Research output: Contribution to journalArticlepeer-review

Abstract

The possible advantage of adding cisplatin (P) to cyclophosphamide (C) + adriamycin (A) in the management of stages III and IV ovarian cancer of epithelial origin was tested in a trial in which 149 patients were randomized to receive, after initial surgery, either CAP (C=600 mg/sqm, A=45 mg/sqm, P=50 mg/sqm) or CA (C=600 mg/sqm, A=45 mg/sqm) every 4 weeks for 6 to 12 cycles, at which time follow-up laparotomy was to be performed in responding or clinically disease-free patients. Fifteen patients were not included in the final analysis and the remaining 134 patients were considered fully or partially evaluable and are used in analysis of response and survival. The complete and partial response rates were 45.6% in the CAP arm and 45.4% in the CA arm, but the CAP regimen is of special importance in patients with bulky disease. Median survival CAP=24 m and CA=24.2 m), time to progression and survival was found not significantly different when CAP and CA were compared. However, more patients in the CA regimen had no macroscopic disease left after surgery than in CAP regimen (11 versus 6) and more patients in the CAP arm had dose reductions and schedule delays than in the CA arm (61.1% versus 38.2%).

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalEuropean Journal of Gynaecological Oncology
Volume11
Issue number5
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study'. Together they form a unique fingerprint.

Cite this